CARLSBAD, Calif., June 15, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that it has deepened its commitment to stem cell research and its customers by signing a non-exclusive agreement with iPS Academia Japan for its induced pluripotent stem (iPS) cell patent portfolio. The worldwide license will enable Life Technologies, a leading provider of innovative life science solutions, to expand its range of products and services for the iPS cell research community.
By leveraging its expertise in stem cell tool manufacturing and its global distribution network, Life Technologies is now positioned to develop and commercialize products designed to create iPS cells and differentiate them into any cell type for use in drug discovery and pre-clinical research. In additional to directly selling iPS cells, the license enables the company to provide iPS cell creation, differentiation and screening services for scientists around the world.
"iPS Academia Japan is pleased to grant a non-exclusive license and build a relationship with Life Technologies Corporation. Because iPS cells are gaining greater attention for uses in drug discovery and disease research as well as other areas of biotechnology, distribution of iPS cell products or provision of services is important for gaining momentum in iPS cell research," said Shosaku Murayama, president and Chief Executive Officer of AJ. "We believe that Life Technologies' business will contribute to boost research and development for practical application of iPS cell technology. We hope for further advancement of the iPS cell technology and its practical use in the coming years and we continue to support expanding the iPS cell technology by licensing our patent portfolio."
Scientists use iPS cell technology to create iPS cells from patient-derived adult cells. The iPS cells can then be differentiated into many primary cell types, such as neurons and hepatocytes, to be studied in the lab. The ability to develop cells from people with particular conditions of interest gives researchers the ability to study the genetics behind patient-specific diseases in an effort to test or develop new potential treatments.
"I am very pleased that Life Technologies, a worldwide biotechnology company, has signed an agreement for Kyoto University Patent," said Professor Shinya Yamanaka, who led the team that was first to generate iPS cells in 2006. "I hope it will speed up the movement towards practical applications of iPS cell technology."
Mark Stevenson, President and COO of Life Technologies, added: "Life Technologies has a heritage of providing the science community with the most innovative solutions designed to accelerate research. With this license now in place, we are furthering our commitment to the stem cell field and to developing a full breadth of products and services for our customers whether they are in basic research, drug discovery and development, or moving toward clinical applications."
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
ABOUT iPS ACADEMIA JAPAN, INC.
iPS Academia Japan, Inc. (AJ) is an affiliate of Kyoto University, and its main role is, among other activities, to manage and utilize the patents and other intellectual properties held/controlled by Kyoto University and other universities in the field of iPSC technologies so that the research results contribute to health and welfare worldwide.
AJ was established in Kyoto in June 2008. AJ's patent portfolio consists of more than 60 patent families (the total number of patent applications is about 220 cases) in the iPSC technology as of April 2012, and about 50 license arrangements have been executed with domestic or international enterprises. For more information, visit www.ips-cell.net.
Life Technologies Contact
|SOURCE Life Technologies Corporation|
Copyright©2012 PR Newswire.
All rights reserved